TROPION-Lung01 Study Design and Baseline demographics

Skip in ESMO Highlight presentation Efficacy endpoint: PFS by HER2 status per cohort Daiichi-Sankyo Median PFS in months (95% CI) Endometrial cancer: IHC 3+ NR (7.3, NR) Endometrial cancer: IHC 2+ 8.5 (4.6, 15.1) -Endometrial cancer: Total 11.1 (7.1, NR) " -O -0 3 6 9 12 15 18 21 -2 24 T 27 30 33 Time from first dose (months) 370 17 40 215 12 14 == 11 10 10 11 7 31 27 21 956 157 8 4 16 14 528 0 1 0 2 1 1 0 All cohorts Probability of PFS 1.0- 0.8- 0.6- Median PFS in months (95% CI) All cohorts: IHC 3+ 11.9 (8.2, 13.0) All cohorts: IHC 2+ 5.4 (4.2, 6.0) All cohorts: Total 6.9 (5.6, 8.0) 1.0- 0.4- 0.2- 0.0- Endometrial cancer Probability of PFS 0.8- 0.6- 0.4- 0.2- 0.0 T -O 0 3 -8 T 6 9 12 -2 T 15 18 21 24 27 30 33 33- Time from first dose (months) Number at risk, month All cohorts: IHC 3+ 75 63 51 39 34 23 19 All cohorts: IHC 2+ 125 78 50 31 20 18 All cohorts: Total 267 185 132 89 68 51 ៩៨ 13 39 212 12 1 9 3 25 6 010 2 0 1 Number at risk, month Endometrial cancer: IHC 3+ 13 Endometrial cancer: IHC 2+ 0 Endometrial cancer: Total 276 1.0- Cervical cancer Probability of PFS 0.8- 0.6- 0.4- 0.2- 0.0 Median PFS in months (95% CI) Cervical cancer: IHC 3+ NR (3.9, NR) Cervical cancer: IHC 2+ 4.8 (2.7, 5.7) Cervical cancer: Total 7.0 (4.2, 11.1) 1.0- Ovarian cancer Probability of PFS 0.8- Median PFS in months (95% CI) Ovarian cancer: IHC 3+ 12.5 (3.1, NR) Ovarian cancer: IHC 2+ 4.1 (2.3, 12.6) Ovarian cancer: Total 5.9 (4.0, 8.3) 0.6- 0.4- 0.2- 0.0- T 0 3 6 9 -CO 12 T 15 T T 18 21 T 24 27 T D- -n 0 3 16 Time from first dose (months) 9 Time from first dose (months) T - T - - 12 15 18 21 24 27 30 Number at risk, month Number at risk, month Cervical cancer: IHC 3+ 8 Cervical cancer: IHC 2+ 20 Cervical cancer: Total 40 28 0000 8 12 752 6 5 3 3 1 1 0 Ovarian cancer: IHC 3+ 11 10 3 0 Ovarian cancer: IHC 2+ 19 11 20 14 9 6 3 1 1 0 Ovarian cancer: Total 40 28 17 551 652 16 4 4 4 12 11 9 27 326 0 1 1 1 1 00 Circle indicates a censored observation Cl, confidence interval; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NR, not reached; PFS, progression-free survival 40 48

View entire presentation